Low Rates of Antifungal Therapeutic Drug Monitoring Among Inpatients Who Received Itraconazole, Posaconazole, or Voriconazole, United States, 2019–2021
Kaitlin Benedict, Jeremy A.W. Gold, Mitsuru Toda, George R. Thompson, Nathan P. Wiederhold, Dallas J. Smith
Abstract
Antifungal therapeutic drug monitoring (TDM) is recommended for hospitalized patients receiving itraconazole, posaconazole, or voriconazole for treatment or prophylaxis. In this analysis of hospital-based data, TDM was uncommonly performed (15.8%) in a large cohort of eligible patients, suggesting missed opportunities to avoid subtherapeutic drug levels and minimize toxicity.
Topics & Concepts
PosaconazoleItraconazoleVoriconazoleMedicineTherapeutic drug monitoringAntifungalDrugFluconazoleAntifungal drugInternal medicinePharmacologyIntensive care medicineDermatologyAntifungal resistance and susceptibilityFungal Infections and StudiesPneumocystis jirovecii pneumonia detection and treatment